S&P 500   4,164.00
DOW   34,156.69
QQQ   309.88
Two Billionaires Are Rigging the Market. Here’s How to Fight Back
The #1 Energy Stock to Buy (Ad)
3 Hot Stocks The Analysts Are Buying 
Is Biotech Immunocore About To Make A 25% Price Move?
The #1 Energy Stock to Buy (Ad)
Why Is Wall Street Loving Amazon So Much? 
Want to Invest in ChatGPT? Then Buy Microsoft Stock
The #1 Energy Stock to Buy (Ad)
Stocks end higher after zig-zagging on Fed chair's comments
Patient Clorox Shareholders Are Cleaning Up
S&P 500   4,164.00
DOW   34,156.69
QQQ   309.88
Two Billionaires Are Rigging the Market. Here’s How to Fight Back
The #1 Energy Stock to Buy (Ad)
3 Hot Stocks The Analysts Are Buying 
Is Biotech Immunocore About To Make A 25% Price Move?
The #1 Energy Stock to Buy (Ad)
Why Is Wall Street Loving Amazon So Much? 
Want to Invest in ChatGPT? Then Buy Microsoft Stock
The #1 Energy Stock to Buy (Ad)
Stocks end higher after zig-zagging on Fed chair's comments
Patient Clorox Shareholders Are Cleaning Up
S&P 500   4,164.00
DOW   34,156.69
QQQ   309.88
Two Billionaires Are Rigging the Market. Here’s How to Fight Back
The #1 Energy Stock to Buy (Ad)
3 Hot Stocks The Analysts Are Buying 
Is Biotech Immunocore About To Make A 25% Price Move?
The #1 Energy Stock to Buy (Ad)
Why Is Wall Street Loving Amazon So Much? 
Want to Invest in ChatGPT? Then Buy Microsoft Stock
The #1 Energy Stock to Buy (Ad)
Stocks end higher after zig-zagging on Fed chair's comments
Patient Clorox Shareholders Are Cleaning Up
S&P 500   4,164.00
DOW   34,156.69
QQQ   309.88
Two Billionaires Are Rigging the Market. Here’s How to Fight Back
The #1 Energy Stock to Buy (Ad)
3 Hot Stocks The Analysts Are Buying 
Is Biotech Immunocore About To Make A 25% Price Move?
The #1 Energy Stock to Buy (Ad)
Why Is Wall Street Loving Amazon So Much? 
Want to Invest in ChatGPT? Then Buy Microsoft Stock
The #1 Energy Stock to Buy (Ad)
Stocks end higher after zig-zagging on Fed chair's comments
Patient Clorox Shareholders Are Cleaning Up
NASDAQ:CHRS

Coherus BioSciences - CHRS Stock Forecast, Price & News

$8.42
+0.02 (+0.24%)
(As of 02/7/2023 12:00 AM ET)
Add
Compare
Today's Range
$8.16
$8.45
50-Day Range
$5.69
$10.52
52-Week Range
$5.58
$14.11
Volume
588,065 shs
Average Volume
1.19 million shs
Market Capitalization
$654.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.50

Coherus BioSciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
96.0% Upside
$16.50 Price Target
Short Interest
Bearish
13.97% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.08
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.87) to ($1.44) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.18 out of 5 stars

Medical Sector

370th out of 1,029 stocks

Biological Products, Except Diagnostic Industry

59th out of 168 stocks

CHRS stock logo

About Coherus BioSciences (NASDAQ:CHRS) Stock

Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and Coherus COMPLETE. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

Receive CHRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Coherus BioSciences and its competitors with MarketBeat's FREE daily newsletter.

CHRS Stock News Headlines

CHRS.O - | Stock Price & Latest News | Reuters
The #1 Energy Stock to Buy
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
CHRS Coherus BioSciences, Inc.
The #1 Energy Stock to Buy
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Should You Invest in Coherus BioSciences (CHRS)?
Coherus BioSciences Earnings Preview
Will Coherus BioSciences (CHRS) Stock Bounce Back?
See More Headlines
Receive CHRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Coherus BioSciences and its competitors with MarketBeat's FREE daily newsletter.

CHRS Company Calendar

Last Earnings
11/07/2021
Today
2/07/2023
Next Earnings (Estimated)
2/16/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CHRS
Fax
N/A
Employees
332
Year Founded
2010

Price Target and Rating

Average Stock Price Forecast
$16.50
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+96.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-287,100,000.00
Net Margins
-116.54%
Pretax Margin
-116.54%

Debt

Sales & Book Value

Annual Sales
$326.55 million
Book Value
$1.27 per share

Miscellaneous

Free Float
68,515,000
Market Cap
$654.91 million
Optionable
Optionable
Beta
0.88

Social Links


Key Executives

  • Denny M. LanfearDenny M. Lanfear
    Chairman, President & Chief Executive Officer
  • McDavid StilwellMcDavid Stilwell
    Chief Financial Officer
  • Vladimir Vexler
    Chief Scientific Officer
  • Richard L. Hameister
    Chief Technical Officer
  • Rosh Dias
    Chief Medical Officer













CHRS Stock - Frequently Asked Questions

Should I buy or sell Coherus BioSciences stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Coherus BioSciences in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CHRS shares.
View CHRS analyst ratings
or view top-rated stocks.

What is Coherus BioSciences' stock price forecast for 2023?

4 analysts have issued twelve-month price targets for Coherus BioSciences' stock. Their CHRS share price forecasts range from $7.00 to $30.00. On average, they anticipate the company's share price to reach $16.50 in the next year. This suggests a possible upside of 96.0% from the stock's current price.
View analysts price targets for CHRS
or view top-rated stocks among Wall Street analysts.

How have CHRS shares performed in 2023?

Coherus BioSciences' stock was trading at $7.92 at the beginning of the year. Since then, CHRS stock has increased by 6.3% and is now trading at $8.42.
View the best growth stocks for 2023 here
.

When is Coherus BioSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 16th 2023.
View our CHRS earnings forecast
.

How were Coherus BioSciences' earnings last quarter?

Coherus BioSciences, Inc. (NASDAQ:CHRS) released its earnings results on Sunday, November, 7th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.12. The biotechnology company earned $82.50 million during the quarter, compared to the consensus estimate of $86.96 million. Coherus BioSciences had a negative trailing twelve-month return on equity of 422.10% and a negative net margin of 116.54%. During the same quarter in the previous year, the business earned $0.33 earnings per share.

What is Dennis M. Lanfear's approval rating as Coherus BioSciences' CEO?

21 employees have rated Coherus BioSciences Chief Executive Officer Dennis M. Lanfear on Glassdoor.com. Dennis M. Lanfear has an approval rating of 95% among the company's employees. This puts Dennis M. Lanfear in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Coherus BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus BioSciences investors own include Halozyme Therapeutics (HALO), Chembio Diagnostics (CEMI), Exelixis (EXEL), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Intelsat (I), Idera Pharmaceuticals (IDRA), Immunomedics (IMMU), Sangamo Therapeutics (SGMO) and Viking Therapeutics (VKTX).

What is Coherus BioSciences' stock symbol?

Coherus BioSciences trades on the NASDAQ under the ticker symbol "CHRS."

Who are Coherus BioSciences' major shareholders?

Coherus BioSciences' stock is owned by many different institutional and retail investors. Top institutional investors include Peregrine Capital Management LLC (1.44%), Scout Investments Inc. (0.85%), AlphaCentric Advisors LLC (0.24%), Legato Capital Management LLC (0.08%), Texas Permanent School Fund (0.06%) and Yousif Capital Management LLC (0.05%). Insiders that own company stock include Dennis M Lanfear, James Healy, Jean-Frederic Viret, Mary T Szela, Mats Wahlstrom, Mcdavid Stilwell, Vincent R Anicetti and Vladimir Vexler.
View institutional ownership trends
.

How do I buy shares of Coherus BioSciences?

Shares of CHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Coherus BioSciences' stock price today?

One share of CHRS stock can currently be purchased for approximately $8.42.

How much money does Coherus BioSciences make?

Coherus BioSciences (NASDAQ:CHRS) has a market capitalization of $654.91 million and generates $326.55 million in revenue each year. The biotechnology company earns $-287,100,000.00 in net income (profit) each year or ($3.60) on an earnings per share basis.

How many employees does Coherus BioSciences have?

The company employs 332 workers across the globe.

Does Coherus BioSciences have any subsidiaries?
The following companies are subsidiares of Coherus BioSciences: Coherus Intermediate Corp, InteKrin, InteKrin Russia, and InteKrin Therapeutics Inc..
Read More
How can I contact Coherus BioSciences?

Coherus BioSciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The official website for the company is www.coherus.com. The biotechnology company can be reached via phone at (650) 649-3530 or via email at darrington@coherus.com.

This page (NASDAQ:CHRS) was last updated on 2/8/2023 by MarketBeat.com Staff